<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55370">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961232</url>
  </required_header>
  <id_info>
    <org_study_id>IRB090650</org_study_id>
    <nct_id>NCT01961232</nct_id>
  </id_info>
  <brief_title>Trans-pulmonary Biomarkers in Pulmonary Hypertension</brief_title>
  <official_title>Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are testing whether the addition of Pulmonary Hypertension-related
      biomarkers, measured across the pulmonary circulation, to the standard hemodynamic
      evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary
      Hypertension therapy and improved patient outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically
      indicated right heart catheterization may be enrolled. Clinical data and blood samples will
      be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasodilator-induced changes in Pulmonary Hypertension biomarkers</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Differences between Pulmonary Hypertension-related biomarkers in pulmonary circulation and  peripheral-venous circulation</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension &amp; WHO group I</arm_group_label>
    <description>Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension &amp; WHO group II</arm_group_label>
    <description>Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Pulmonary Hypertension</arm_group_label>
    <description>Participants without Pulmonary Hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Connective Tissue Disease</arm_group_label>
    <description>Participants without PH, but with connective tissue disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pulmonary Vascular Clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Undergoing RHC for PH evaluation

        Exclusion Criteria:

          -  Anemia defined as Hgb &lt; 10 g/dL and HCT &lt; 30

          -  Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day
             of the procedure)

          -  Left ventricular ejection fraction ≤ 40%

          -  Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on
             the day of the procedure)

          -  IPF, CTEPH, COPD/OSA as the dominant etiology of PH

          -  Patient is currently taking PH medication or long-acting nitrates at the time of
             their RHC.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Monahan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Maynard, RN</last_name>
    <phone>615-936-1720</phone>
    <email>laura.e.maynard@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth Monahan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Monahan K, Scott TA, Su YR, Lenneman CG, Zhao DX, Robbins IM, Hemnes AR. Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension. Pulm Circ. 2013 Apr;3(2):345-9. doi: 10.4103/2045-8932.114762.</citation>
    <PMID>24015334</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Kenneth Monahan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>biomarker</keyword>
  <keyword>cardiac</keyword>
  <keyword>circulation</keyword>
  <keyword>heart disease</keyword>
  <keyword>lung disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
